查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1729655

日本糖尿病市场报告：2025-2033

Japan Diabetes Market Report: 2025-2033
出版日期: | 出版商: IMARC | 英文 122 Pages | 商品交期: 5-7个工作天内

价格

2024 年日本糖尿病市场规模达 56 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 74 亿美元，2025-2033 年期间的成长率 (CAGR) 为 3.2%。市场的主要驱动因素是老年人口的成长、糖尿病盛行率的上升、政府支持措施带来的医疗支出的增加以及治疗方案的技术进步。

日本糖尿病市场分析：

  • 主要市场驱动因素：由于生活方式的改变和人口老化，日本糖尿病盛行率上升是主要的成长诱因。此外，最近的研究表明，糖尿病患者数量仍在增长，这增加了日本糖尿病市场的需求。此外，政府也资助并实施了多项健康倡议，以加强糖尿病的治疗和管理。其中包括糖尿病治疗补助和鼓励市场扩张的公共卫生措施。
  • 主要市场趋势：胰岛素帮浦和连续血糖监测仪（CGM）等先进的糖尿病护理技术越来越受欢迎。此外，市场正见证着个人化治疗计划和定製药物的趋势，这是由对遗传变量和独特患者需求的更多研究推动的，以提供更高效和专业化的糖尿病管理解决方案。
  • 竞争格局：日本糖尿病市场由大型国际製药和医疗器材企业主导，因为他们广泛的产品和尖端技术帮助他们保持竞争力。此外，日本公司也针对日本患者的需求提供创新和客製化解决方案。
  • 挑战与机会：市场挑战包括严格的监管规定和新型糖尿病疗法的漫长审批程序。另一方面，老年人口的不断增长为专门针对这一人群的糖尿病治疗和管理计划的发展提供了巨大的机会。此外，远距医疗和行动健康应用等数位健康技术的发展为更好地参与患者和糖尿病管理创造了新的可能性。

日本糖尿病市场趋势：

糖尿病盛行率上升

日本糖尿病市场的成长是由糖尿病发病率的上升所推动的。根据国际糖尿病联盟（IDF）的报告，截至 2021 年，该国糖尿病患者人数为 93,187,400 人，成年人糖尿病盛行率为 11.8%，即 11,004,999 例。因此，由于对包括尖端药物和监测设备在内的完整糖尿病护理解决方案的需求不断增加，市场正在不断扩大。此外，随着患者数量的增加，製药公司和医疗保健专业人员被迫创造和提供各种各样的治疗方案，以满足患者的不同需求。此外，糖尿病病例的增加也增加了针对糖尿病的专门医疗服务，试图改善患者的治疗效果和生活品质。因此，这一趋势推动了抗糖尿病药物的销售，并促进了创新血糖监测技术市场的发展，这些技术有望提供更准确、更人性化的选择，从而为日本糖尿病市场创造了积极的前景。

老年人口不断增加

根据总务省报道，截至2023年9月15日，日本65岁以上的老龄人口数已达3,622.7万人，占总人口的比例将增加0.1个百分点，达到29.1%，创历史新高。此外，老年人更容易患第 2 型糖尿病，这增加了对专门的糖尿病管理计划和产品的需求。人口结构的这种变化促使医疗保健组织和临床医生专注于老年糖尿病的治疗，从而推动了针对老年人群需求的药物治疗、营养指导和患者教育的进步。此外，人口老化影响了多种需求服务和产品，这些服务和产品使用简单、侵入性低，非常适合老年患者，并增加了必要的糖尿病治疗量。

政府支持措施和医疗支出

糖尿病市场受到日本政府积极推动的医疗保健支出政策的推动，其中包括用于治疗糖尿病等慢性疾病的大量预算。根据Frontiers统计，2020年，日本全国医疗支出飙升至43兆日圆（3,040亿美元），几乎是1990年以来的两倍。这意味着该国国内生产毛额的成长从4.6%上升到8.0%。此外，政府确保在糖尿病护理方面投入足够的资金，使治疗更加容易获得且价格更合理。这些项目涵盖了从复杂的治疗选择到初级预防的所有内容，糖尿病护理的基础正在改善。此外，政府采取了许多倡议，集中进行筛检和公共卫生运动，以降低糖尿病的盛行率，同时改善社区层面的糖尿病管理，这些倡议正在影响市场的成长。因此，这些全面的健康政策透过提高意识和早期发现，同时将先进的糖尿病照护纳入公共卫生系统，支持日本糖尿病市场的成长。

日本糖尿病市场细分：

按细分市场划分：

  • 口服抗糖尿病药物
  • 胰岛素

胰岛素占大部分市场份额

由于老龄人口中糖尿病的盛行率不断上升，以及为有效管理血糖而越来越多地采用胰岛素疗法，胰岛素占据了相当大的市场份额。此外，以高效着称的日本医疗保健系统大力支持糖尿病护理，使人们能够广泛获得胰岛素治疗。此外，市场也受惠于胰岛素配方和输送系统的进步，从而提高了患者的依从性和治疗效果。此外，日本政府积极的健康措施旨在提高人们对糖尿病的认识和筛检，进一步推动了对胰岛素的需求。此外，该领域的成长还得益于国内製药公司与全球糖尿病护理领导者之间的合作，旨在创新和扩大针对日本患者独特需求的尖端胰岛素解决方案的可用性。因此，主要参与者正在推出先进的产品变体来满足这些需求。例如，2023 年 3 月，Health2Sync 在日本东京和台湾台北宣布其 Health2Sync 应用程式的最新更新，现在包括来自 Mallya Cap 的胰岛素资料，Mallya Cap 是由 Biocorp 製造并由诺和诺德在日本销售的胰岛素笔连接设备。此次合作是世界上首次整合此类资料，旨在透过追踪各种健康指标（例如胰岛素注射记录）来帮助接受胰岛素治疗的患者。由于这些创新，日本糖尿病市场预测显示胰岛素领域将继续占据市场主导地位。

日本糖尿病市场新闻：

  • 2023 年 4 月 18 日，日本礼来公司和田边三菱製药株式会社 (MTPC) 宣布在日本推出 Mounjaro 皮下注射剂 2.5 毫克/5 毫克 ATEOS，这是一种有前途的 2 型糖尿病治疗替代方案。
  • 2024 年 5 月 22 日，三菱化学集团旗下、总部位于日本大阪中央区的田边三菱製药株式会社 (MTPC) 宣布推出 SGLT2 抑制剂 CANAGLU(R) OD 片剂 100 毫克，为第 2 型糖尿病提供新的治疗选择。 CANAGLU(R) OD 片剂只需少量水分（如唾液）即可快速崩解，更容易吞嚥。此功能对于需要持续服药的 2 型糖尿病患者特别有益，因为它提高了治疗的便利性和依从性。

本报告回答的关键问题：

  • 日本糖尿病市场目前表现如何？未来几年又将如何表现？
  • COVID-19 对日本糖尿病市场有何影响？
  • 日本糖尿病市场按细分如何划分？
  • 日本糖尿病市场的价值链分为哪些阶段？
  • 日本糖尿病市场的主要驱动因素和挑战是什么？
  • 日本糖尿病市场的结构是怎么样的？主要参与者是谁？
  • 日本糖尿病市场的竞争程度如何？

本报告回答的关键问题：

  • 日本糖尿病市场目前表现如何？未来几年又将如何表现？
  • COVID-19 对日本糖尿病市场有何影响？
  • 日本糖尿病市场按细分如何划分？
  • 日本糖尿病市场的价值链分为哪些阶段？
  • 日本糖尿病市场的主要驱动因素和挑战是什么？
  • 日本糖尿病市场的结构是怎么样的？主要参与者是谁？
  • 日本糖尿病市场的竞争程度如何？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：糖尿病疾病概述

  • 什么是糖尿病？
  • 糖尿病诊断与治疗
    • 诊断
    • 治疗
  • 糖尿病併发症

第六章：日本糖尿病流行病学

  • 糖尿病人口和盛行率
  • 人口及盛行率：依糖尿病类型（1型和2型）
  • 人口及盛行率：按地区
  • 人口及盛行率：依性别
  • 人口及盛行率：依年龄组

第七章：日本糖尿病市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测
  • SWOT分析
  • 价值链分析
  • 波特五力分析
  • 市场区隔：按细分市场

第八章：竞争格局

  • 市场结构
  • 关键参与者简介
Product Code: SR112025A561

The Japan diabetes market size reached USD 5.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.4 Billion by 2033, exhibiting a growth rate (CAGR) of 3.2% during 2025-2033. The market is primarily driven by the growing geriatric population, increased prevalence of diabetes, enhanced healthcare spending with supportive government initiatives, and technological advancements in treatment options.

Japan Diabetes Market Analysis:

  • Major Market Drivers: The rising prevalence of diabetes in Japan due to the changing lifestyles and an aging population represents a major growth-inducing factor. In addition, recent research indicates that the diabetic patient population is still growing, which is increasing the Japan diabetes market demand. Besides, the government has funded and executed several health initiatives to enhance the treatment and management of diabetes. These include diabetes treatment subsidies and public health initiatives that encourage market expansion.
  • Key Market Trends: Advanced diabetes care technology like insulin pumps and continuous glucose monitors (CGMs) are becoming more popular. Moreover, the market is witnessing a trend toward individualized treatment plans and customized medicines, which is driven by greater research into genetic variables and unique patient demands to deliver more efficient and specialized diabetes management solutions.
  • Competitive Landscape: The Japanese diabetes market is dominated by giant international pharmaceutical and medical device businesses, as their wide range of products and cutting-edge technology help them to stay competitive. Additionally, Japanese companies are offering innovations and customized solutions specific to the requirements of Japanese patients.
  • Challenges and Opportunities: Challenges in the market include stringent regulatory regulations and protracted approval procedures for novel diabetic therapies. On the other hand, the growing geriatric population offers substantial opportunities for the development of diabetes treatment and management programs specifically designed for this demographic. Besides, the development of digital health technologies, such as telemedicine and mobile health apps, creates new possibilities for better patient engagement and diabetes management.

Japan Diabetes Market Trends:

Rising Diabetes Prevalence

The growth of the diabetes market in Japan is driven by the rising incidence of diabetes. According to the International Diabetes Federation (IDF) reports, with 93,187,400 individuals in the country as of 2021, the prevalence rate of diabetes is 11.8% or 11,004,999 cases among adults. As a result, the market is expanding due to the increasing need for complete diabetes care solutions, which include cutting-edge drugs and monitoring equipment. Moreover, pharmaceutical businesses and healthcare professionals are compelled by the increasing number of patients to create and offer a wide array of treatment alternatives that address the diverse demands of their patients. In addition, the rise in diabetes cases has increased diabetes-specific healthcare services that attempt to enhance patient outcomes and quality of life. Hence, this trend has propelled the sales of anti-diabetic medications and boosted the market for innovative glucose monitoring technologies that promise more accurate and user-friendly options, thus creating a positive Japan diabetes market outlook.

Growing Geriatric Population

As reported by the Ministry of Internal Affairs and Communications, Japan's elderly population, those aged 65 and above, reached 36,227 thousand as of September 15, 2023. Moreover, the proportion of seniors in the overall population increased by 0.1% points to 29.1%, the highest percentage ever recorded. Additionally, the elderly are more susceptible to type 2 diabetes, which escalates the need for specialized diabetes management programs and products. This change in the population motivates healthcare organizations and clinicians to concentrate on the treatment of geriatric diabetes, resulting in advancements in medication therapy, nutritional guidance, and patient education customized to the needs of the geriatric population. Besides, the aging population influences several services and products that are in demand, offer simple use and low invasiveness, which are ideal for senior patients, and increase the volume of diabetic treatments that are necessary.

Supportive Government Initiatives and Healthcare Spending

The diabetes market is driven by the government of Japan's aggressive approach to healthcare spending, which includes a sizeable budget for treating chronic illnesses like diabetes. According to Frontiers, in 2020, Japan's national medical spending skyrocketed to 43 Trillion yen (304 Billion USD), nearly doubling from past figures since 1990. This indicates an increase in the nation's gross domestic output from 4.6% to 8.0%. In addition, the government ensures that enough money is spent on diabetes care, which makes treatments more accessible and reasonably priced. The foundation of diabetes care is being improved due to these programs, which cover everything from sophisticated treatment choices to primary prevention. In addition, numerous government initiatives concentrated on screenings and public health campaigns to lower the prevalence of diabetes while improving its management at the community level are influencing the market growth. Hence, these comprehensive health policies support Japan diabetes market growth by increasing awareness and early detection while integrating advanced diabetes care into the public health system.

Japan Diabetes Market Segmentation:

Breakup by Segment:

  • Oral Antidiabetics
  • Insulin

Insulin accounts for the majority of the market share

Insulin reflects a substantial portion of the market share due to the increasing prevalence of diabetes among the aging population and the rising adoption of insulin therapies for effective glucose management. Additionally, Japan's healthcare system, renowned for its efficiency, extensively supports diabetes care, enabling widespread access to insulin treatments. Moreover, the market benefits from advancements in insulin formulations and delivery systems, which enhance patient adherence and outcomes. Besides, the Japanese government's proactive health initiatives aim to improve diabetes awareness and screening, further driving the demand for insulin. Furthermore, this segment's growth is also fueled by collaborations between domestic pharmaceutical companies and global diabetes care leaders, aiming to innovate and expand the availability of cutting-edge insulin solutions tailored to the unique needs of Japanese patients. Hence key players are introducing advanced product variants to meet these needs. For instance, in March 2023, in Tokyo Japan, and Taipei, Taiwan, Health2Sync, announced the recent update of its Health2Sync App now including insulin data from the Mallya Cap, a connected device for insulin pens created by Biocorp and marketed in Japan by Novo Nordisk. This collaboration introduces the world's first integration of this type of data and is designed to aid patients undergoing insulin treatment by tracking various health metrics, such as insulin injection records. Due to these innovations, the Japan diabetes market forecast states that insulin segment will continue to dominate the market.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have been provided.
  • At present, key players in the market are actively enhancing growth through strategic collaborations, advanced research and development (R&D) initiatives, and educational programs to improve diabetes management. Additionally, companies like Novo Nordisk and Sanofi are investing heavily in the development of next-generation insulin therapies and glucose monitoring systems tailored to meet the specific needs of Japanese patients, thus accounting for the Japan diabetes market share. These firms collaborate closely with local healthcare providers to ensure broad distribution and integration of their products into daily medical practice. Furthermore, these market leaders support extensive patient education campaigns to increase awareness about diabetes symptoms, treatment options, and lifestyle adjustments necessary for effective disease management. These comprehensive strategies strengthen their market position and significantly contribute to improving patient outcomes in Japan. For instance, on 29 March 2023, Maryland, Astellas Pharma Inc. announced its partnership with Roche Diabetes Care Japan Co., Ltd. This partnership focuses on the development and commercialization of the globally recognized Accu-Chek Guide Me blood glucose monitoring system, noted for its high accuracy, in conjunction with BlueStar(R)*1. BlueStar, an FDA-approved digital health solution for managing diabetes, is developed by Welldoc, Inc. and is available in the U.S. and Canada. Astellas and Welldoc are collaboratively advancing BlueStar's development in Japan. Astellas plans to seek regulatory approval and reimbursement for this integrated medical product in the future.

Japan Diabetes Market News:

  • 18 April 2023, Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation (MTPC) have declared the introduction of the Mounjaro subcutaneous injection 2.5 mg / 5 mg ATEOS in Japan which represents a promising treatment alternative for type 2 diabetes.
  • 22 May 2024, Mitsubishi Tanabe Pharma Corporation (MTPC), part of the Mitsubishi Chemical Group and headquartered in Chuo-ku, Osaka, Japan, announced the release of the SGLT2 inhibitor CANAGLU(R) OD Tablets 100 mg, to provide a new treatment option for type 2 diabetes mellitus. The CANAGLU(R) OD Tablets are designed to disintegrate quickly with just a slight amount of moisture, such as saliva, facilitating easier ingestion. This feature is particularly beneficial for individuals with type 2 diabetes requiring continuous medication, as it enhances convenience and adherence to treatment.

Key Questions Answered in This Report:

  • How has the Japan diabetes market performed so far, and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan diabetes market?
  • What is the breakup of the Japan diabetes market on the basis of segment?
  • What are the various stages in the value chain of the Japan diabetes market?
  • What are the key driving factors and challenges in the Japan diabetes market?
  • What is the structure of the Japan diabetes market, and who are the key players?
  • What is the degree of competition in the Japan diabetes market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Diabetes Disease Overview

  • 5.1 What is Diabetes?
  • 5.2 Diabetes Diagnosis and Treatment
    • 5.2.1 Diagnosis
    • 5.2.2 Treatment
  • 5.3 Diabetes Complications

6 Japan Diabetes Epidemiology

  • 6.1 Diabetes Population and Prevalence Rates
  • 6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
  • 6.3 Population and Prevalence Rates by Region
  • 6.4 Population and Prevalence Rates by Gender
  • 6.5 Population and Prevalence Rates by Age Group

7 Japan Diabetes Market

  • 7.1 Market Overview
  • 7.2 Market Performance
  • 7.3 Impact of COVID-19
  • 7.4 Market Forecast
  • 7.5 SWOT Analysis
    • 7.5.1 Overview
    • 7.5.2 Strengths
    • 7.5.3 Weaknesses
    • 7.5.4 Opportunities
    • 7.5.5 Threats
  • 7.6 Value Chain Analysis
  • 7.7 Porter's Five Forces Analysis
    • 7.7.1 Overview
    • 7.7.2 Bargaining Power of Buyers
    • 7.7.3 Bargaining Power of Suppliers
    • 7.7.4 Degree of Competition
    • 7.7.5 Threat of New Entrants
    • 7.7.6 Threat of Substitutes
  • 7.8 Market Breakup by Segment
    • 7.8.1 Japan Oral Antidiabetics Market
      • 7.8.1.1 Historical Market Trends
      • 7.8.1.2 Market Breakup by Class
      • 7.8.1.3 Market Shares of Key Players
      • 7.8.1.4 Market Forecast
    • 7.8.2 Japan Insulin Market
      • 7.8.2.1 Historical Market Trends
      • 7.8.2.2 Market Breakup by Class
      • 7.8.2.3 Market Shares of Key Players
      • 7.8.2.4 Market Forecast

8 Competitive Landscape

  • 8.1 Market Structure
  • 8.2 Profiles of Key Players

List of Figures

  • Figure 1: The Impact of Diabetes in the Human Body
  • Figure 2: Diabetes Complications
  • Figure 3: Global: Breakup of Diabetes Patients by Region, (in %) 2024 & 2033
  • Figure 4: Body Mass Index and Relative risk of Type-2 Diabetes
  • Figure 5: Japan: Total Number of Diabetes Patients (in 000), 2019-2024
  • Figure 6: Japan: Total Number of Diabetes Patients Forecast (in 000), 2025-2033
  • Figure 7: Japan (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2019-2024
  • Figure 8: Japan (Type1 & Type2): Total Number of Diabetes Patients Forecast (in 000), 2025-2033
  • Figure 9: Japan (Urban & Rural): Total Number of Diabetes Patients (in 000), 2019-2024
  • Figure 10: Japan (Urban & Rural): Total Number of Diabetes Patients Forecast (in 000), 2025-2033
  • Figure 11: Japan (Male & Female): Total Number of Diabetes Patients (in 000), 2019-2024
  • Figure 12: Japan (Male & Female): Total Number of Diabetes Patients Forecast (in 000), 2025-2033
  • Figure 13: Japan: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2019-2024
  • Figure 14: Japan: Total Number of Diabetes Patients Forecast by Age Group (20-39), (40-59) & (60-79) (in 000), 2025-2033
  • Figure 15: Japan: Diabetes Drug Industry Overview
  • Figure 16: Japan: Diabetes Drug Market: Sales Value (in Billion USD), 2019-2024
  • Figure 17: Japan: Diabetes Drug Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 18: Japan: Diabetes Drug Market: SWOT Analysis
  • Figure 19: Japan: Diabetes Drug Market: Value Chain Analysis
  • Figure 20: Japan: Diabetes Drug Market: Porters Five Forces Analysis
  • Figure 21: Japan: Diabetes Drug Market: Breakup of Insulin and Oral Antidiabetics (in %), 2019-2024
  • Figure 22: Japan: Diabetes Drug Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2025-2033
  • Figure 23: Japan: Oral Antidiabetics Market: Sales Value (in Million USD), 2019-2024
  • Figure 24: Japan: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2019 & 2024
  • Figure 25: Japan: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
  • Figure 26: Japan: Oral Antidiabetics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Japan: Insulin Market: Sales Value (in Million USD), 2019-2024
  • Figure 28: Japan: Breakup of Insulin Market by Class (in %), 2024
  • Figure 29: Japan: Insulin Market: Sales Share of Key Players (in %)
  • Figure 30: Japan: Insulin Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

  • Table 1: Diagnosis of Diabetes
  • Table 2: Global: Diabetes Population Breakup by Country (in 000's), 2024 and 2033
  • Table 3: Japan: Total Prevalence & Number of Diabetes Patients, 2019, 2024 & 2033
  • Table 4: Japan (Type1 & Type2): Total Prevalence & Number of Diabetes Patients, 2019, 2024 & 2033
  • Table 5: Japan (Urban & Rural): Total Prevalence & Number of Diabetes Patients, 2019, 2024 & 2033
  • Table 6: Japan (Male & Female): Total Prevalence & Number of Diabetes Patients, 2019, 2024 & 2033
  • Table 7: Japan: Total Prevalence & Number of Diabetes Patients by Age Group (20-39, 40-59, 60-79 - in Millions), 2019, 2024 & 2033
  • Table 8: Japan: Diabetes Drug Market: Competitive Structure